(Total Views: 508)
Posted On: 09/29/2023 6:03:13 PM
Post# of 148876
Don't you wonder who their CRO was, that failed to collect data properly?
This is a SMALL biotech that has a weight-loss drug that would compete with the multi-billion profits that the Big Pharmas are making on these drugs. What a shocking, amazing, unprecedented happening, that a CRO would harm this company by failing to collect data properly. I'm shocked..... SHOCKED..... ! ! ! ! !
Wouldn't it be great if it turned out to be NSF?
This is a SMALL biotech that has a weight-loss drug that would compete with the multi-billion profits that the Big Pharmas are making on these drugs. What a shocking, amazing, unprecedented happening, that a CRO would harm this company by failing to collect data properly. I'm shocked..... SHOCKED..... ! ! ! ! !
Quote:
The biotech, which was co-founded by, and works with, Schrödinger, had planned to share obesity data from a phase 2a trial that could support its differentiation argument by the end of the year. However, a clinical site failed to collect weight data for 24 of the 40 participants at the final, Week 12 visit, forcing Structure to enroll additional participants. As such, while the diabetes cohort will report out as planned, Structure delayed obesity data to the first half of next year. Structure also aims to enter phase 2b in 2024.
https://www.fiercebiotech.com/biotech/structu...on-mistake
Wouldn't it be great if it turned out to be NSF?
(3)
(0)Scroll down for more posts â–¼
